A detailed history of New Edge Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 452,918 shares of ABBV stock, worth $80.1 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares
452,918
Previous 441,911 2.49%
Holding current value
$80.1 Million
Previous $75.8 Million 18.0%
% of portfolio
0.6%
Previous 0.56%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $1.8 Million - $2.19 Million
11,007 Added 2.49%
452,918 $89.4 Million
Q2 2024

Aug 15, 2024

BUY
$154.79 - $180.76 $8.03 Million - $9.38 Million
51,874 Added 13.3%
441,911 $75.8 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $250,118 - $284,986
1,565 Added 0.4%
390,037 $71 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $417,891 - $470,643
3,037 Added 0.79%
388,472 $60.2 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $6.67 Million - $7.72 Million
49,902 Added 14.87%
385,435 $57.5 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $27.9 Million - $34.7 Million
210,289 Added 167.9%
335,533 $45.2 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $46,709 - $53,792
-323 Reduced 0.26%
125,244 $20 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $806,347 - $967,022
5,830 Added 4.87%
125,567 $20.3 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $236,612 - $271,378
1,763 Added 1.49%
119,737 $16.1 Million
Q2 2022

Aug 09, 2022

SELL
$137.62 - $174.96 $487,450 - $619,708
-3,542 Reduced 2.91%
117,974 $18.1 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $2.65 Million - $3.29 Million
20,102 Added 19.82%
121,516 $19.7 Million
Q4 2021

Feb 17, 2022

BUY
$107.43 - $135.93 $4.93 Million - $6.24 Million
45,909 Added 82.71%
101,414 $13.7 Million
Q3 2021

Oct 29, 2021

BUY
$106.4 - $120.78 $994,201 - $1.13 Million
9,344 Added 20.24%
55,505 $5.99 Million
Q2 2021

Jul 22, 2021

BUY
$105.21 - $117.21 $619,371 - $690,015
5,887 Added 14.62%
46,161 $5.2 Million
Q1 2021

Apr 26, 2021

BUY
$102.3 - $112.62 $220,661 - $242,921
2,157 Added 5.66%
40,274 $4.36 Million
Q4 2020

Jan 27, 2021

SELL
$80.49 - $108.67 $184,402 - $248,962
-2,291 Reduced 5.67%
38,117 $4.08 Million
Q3 2020

Nov 03, 2020

BUY
$85.91 - $100.83 $363,141 - $426,208
4,227 Added 11.68%
40,408 $3.54 Million
Q2 2020

Jul 29, 2020

BUY
$73.37 - $98.18 $452,913 - $606,065
6,173 Added 20.57%
36,181 $3.55 Million
Q1 2020

May 04, 2020

SELL
$64.5 - $97.79 $629,455 - $954,332
-9,759 Reduced 24.54%
30,008 $2.29 Million
Q4 2019

Jan 31, 2020

BUY
$72.13 - $90.25 $111,801 - $139,887
1,550 Added 4.06%
39,767 $3.52 Million
Q3 2019

Nov 06, 2019

BUY
$62.98 - $75.72 $192,718 - $231,703
3,060 Added 8.7%
38,217 $2.9 Million
Q2 2019

Aug 05, 2019

SELL
$65.7 - $83.98 $89,286 - $114,128
-1,359 Reduced 3.72%
35,157 $2.56 Million
Q1 2019

May 09, 2019

SELL
$77.14 - $90.79 $873,533 - $1.03 Million
-11,324 Reduced 23.67%
36,516 $171,000
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $112,337 - $138,542
1,443 Added 3.11%
47,840 $4.41 Million
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $793,877 - $882,542
8,929 Added 23.83%
46,397 $4.39 Million
Q2 2018

Jul 19, 2018

BUY
$89.78 - $106.23 $1.45 Million - $1.71 Million
16,131 Added 75.6%
37,468 $3.49 Million
Q1 2018

May 11, 2018

BUY
$92.01 - $123.21 $148,044 - $198,244
1,609 Added 8.16%
21,337 $1.95 Million
Q4 2017

Feb 08, 2018

BUY
$89.56 - $98.21 $8,149 - $8,937
91 Added 0.46%
19,728 $1.96 Million
Q3 2017

Nov 13, 2017

SELL
$69.85 - $89.22 $98,628 - $125,978
-1,412 Reduced 6.71%
19,637 $1.78 Million
Q2 2017

Aug 16, 2017

BUY
N/A
21,049
21,049 $0

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.